波形蛋白在肝细胞癌中的研究进展

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (2): 238-242.

波形蛋白在肝细胞癌中的研究进展

董保龙^1,2, 韩彩文¹, 史明¹, 郑文学¹, 杨晓军^1,2*

1.甘肃中医药大学临床学院,甘肃兰州 730000;
2.甘肃省人民医院普外二科, 甘肃兰州 730000

收稿日期:2019-09-19 修回日期:2019-12-22 出版日期:2020-02-05 发布日期:2020-02-05
通讯作者: ^*yangxjmd@aliyun.com
基金资助:
国家自然科学基金(81260326,81660398);甘肃省自然科学基金(17JR5RA034)

Progress of vimentin in hepatocellular carcinoma

DONG Bao-long^1,2, HAN Cai-wen¹, SHI Ming¹, ZHENG Wen-xue¹, YANG Xiao-jun^1,2*

1. The Clinical Medical College, Gansu University of Traditional Chinese Medicine, Lanzhou 730000;
2. The 2nd Department of General Surgery, Gansu Provincial Hospital, Lanzhou 730000, China

Received:2019-09-19 Revised:2019-12-22 Online:2020-02-05 Published:2020-02-05
Contact: ^*yangxjmd@aliyun.com

摘要/Abstract

摘要： 上皮-间质转化(EMT)是肝细胞癌(HCC)侵袭转移和耐药的重要机制。波形蛋白(VIM)作为EMT的标志性分子,参与调控EMT和形成间质表型肿瘤干细胞;以及VIM甲基化和外泌体直接或间接分泌VIM,促进HCC侵袭增殖、化疗耐药以及复发转移。另外,VIM结合甲胎蛋白(AFP)诊断HCC时特异性和灵敏度显著提高,其表达与HCC预后不良密切相关。

关键词: 波形蛋白, 肿瘤干细胞, VIM甲基化, 外泌体

Abstract: Epithelial-mesenchymal transition (EMT) is a critical mechanism related to invasion, metastasis and drug resistance. Vimentin(VIM), as the biomarker of EMT, functions in regulating EMT and forms epithelial-like cancer stem cells and itself methylation, and exosomes excrete VIM directly or indirectly, which leads to invasiveness and proliferation, chemotherapy resistance and postoperative recurrence of HCC. Importantly, combine detection of circulating VIM and AFP level in patients' serum samples, significantly improved the sensitivity and specificity for diagnosis of HCC, and predict poor prognosis.

Key words: vimentin, cancer stem cells, VIM methylation, exosomes

中图分类号:

R735.7

董保龙, 韩彩文, 史明, 郑文学, 杨晓军. 波形蛋白在肝细胞癌中的研究进展[J]. 基础医学与临床, 2020, 40(2): 238-242.

DONG Bao-long, HAN Cai-wen, SHI Ming, ZHENG Wen-xue, YANG Xiao-jun. Progress of vimentin in hepatocellular carcinoma[J]. Basic & Clinical Medicine, 2020, 40(2): 238-242.

参考文献

[1]Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144: 1941-1953.
[2]Akinyemiju T, Abera S, Ahmed MM, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015[J]. JAMA Oncol, 2017,3:1683-1691.
[3]Brabletz T, Kalluri R, Nieto MA, et al. EMT in cancer[J]. Nat Rev Cancer,2018,18:128-134.
[4]Cho ES, Kang HE, Kim NH, et al. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)[J]. Arch Pharm Res, 2019,42:14-24.
[5]Huang R, Zong X. Aberrant cancer metabolism in epithelial-mesenchymal transition and cancer metastasis: Mechanisms in cancer progression[J]. Crit Rev Oncol Hematol,2017, 115:13-22.
[6]Idriss NK, Fakhry M, Imam HM,et al. Analysis of lamin B1, vimentin and anti-ku86 as prospective biomarkers of hepatocellular carcinoma in patients with hepatitis C virus Infection[J]. Cell Physiol Biochem,2019, 52:595-605.
[7]Dong Q, Zhu X, Dai C, et al. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin[J]. Oncotarget,2016,7:12997-13012.
[8]成超, 李海洋, 叶朝阳,等.波形蛋白在原发性肝癌组织中的表达及临床意义[J].重庆医学,2017,46: 4714-4717.
[9]Ghosh S, Ahrens Wa, Phatak Su, et al. Association of filamin A and vimentin with hepatitis C virus proteins in infected human hepatocytes[J]. J Viral Hepat,2011,18: e568-577.
[10]Pan TL, Wang PW, Huang CC, et al. Network analysis and proteomic identification of vimentin as a key regulator associated with invasion and metastasis in human hepatocellular carcinoma cells[J]. J Proteomics,2012, 75:4676-4692.
[11]Hu L, Ye H, Huang G, et al. Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21[J]. Tumour Biol,2016,37:2691-2702.
[12]Zhu QS, Rosenblatt K, Huang KL, et al. Vimentin is a novel AKT1 target mediating motility and invasion[J]. Oncogene,2011, 30:457-470.
[13]Chen Z, Yu W, Zhou Q, et al. A Novel lncRNA IHS promotes tumor proliferation and metastasis in HCC by regulating the ERK- and AKT/GSK-3beta-signaling pathways[J]. Mol Ther Nucleic Acids,2019,16:707-720.
[14]Gramantieri L, Baglioni M, Fornari F, et al. LncRNAs as novel players in hepatocellular carcinoma recurrence[J]. Oncotarget,2018; 9:35085-35099.
[15]Chang L, Li C, Lan T, et al. Decreased expression of long non-coding RNA GAS5 indicates a poor prognosis and promotes cell proliferation and invasion in hepatocellular carcinoma by regulating vimentin[J]. Mol Med Rep, 2016, 13:1541-1550.
[16]Hodeib H, Elshora O, Selim A, et al. Serum midkine and osteopontin levels as diagnostic biomarkers of hepatocellular carcinoma[J]. Electron Physician,2017,9:3492-3498.
[17]Hou G, Zhao Q, Zhang M, et al. LSD1 regulates Notch and PI3K/Akt/mTOR pathways through binding the promoter regions of Notch target genes in esophageal squamous cell carcinoma[J]. Onco Targets Ther,2019, 12:5215-5225.
[18]Laisne M, Gupta N, Kirsh O, et al. Mechanisms of DNA methyltransferase recruitment in mammals[J]. Genes,2018. doi: 10.3390/genes9120617.
[19]Holmila R, Sklias A, Muller DC, et al. Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma[J]. PLoS One, 2017, 12: e0174265. doi: 10.1371/journal.pone.0174265.
[20]Kitamura Y, Shirahata A, Sakuraba K, et al. Aberrant methylation of the Vimentin gene in hepatocellular carcinoma[J]. Anticancer Res,2011,31:1289-1291.
[21]Topcul M,Cetin I. Clinical significance of epithelial- mesenchymal transition and cancer stem cells[J].BUON,2016,21: 312-319.
[22]Mitra A, Satelli A, Xia X, et al. Cell-surface Vimentin: A mislocalized protein for isolating csVimentin (+) CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers[J]. Int J Cancer,2015, 137:491-496.
[23]徐先云, 严俊, 李汛. 外泌体在肝癌中的研究进展及应用前景[J]基础医学与临床, 2018, 38:107-111.
[24]Hu JL, Wang W, Lan XL, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer[J]. Mol cancer,2019, 18:91. doi: 10.1186/s12943-019-1019-x.
[25]Chen L, Guo P, He Y, et al. HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway[J]. Cell Death Dis,2018, 9:513. doi: 10.1038/s41419-018-0534-9.